>
Switch to:

Bio-Techne Operating Margin %

: 28.56% (As of Jun. 2021)
View and export this data going back to 1992. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Bio-Techne's Operating Income for the three months ended in Jun. 2021 was $74.0 Mil. Bio-Techne's Revenue for the three months ended in Jun. 2021 was $259.0 Mil. Therefore, Bio-Techne's Operating Margin % for the quarter that ended in Jun. 2021 was 28.56%.

Warning Sign:

Bio-Techne Corp operating margin has been in 5-year decline. The average rate of decline per year is -4.4%.

The historical rank and industry rank for Bio-Techne's Operating Margin % or its related term are showing as below:

NAS:TECH' s Operating Margin % Range Over the Past 10 Years
Min: 20.15   Med: 27.95   Max: 52.16
Current: 26.07

20.15
52.16

NAS:TECH's Operating Margin % is ranked higher than
97% of the 265 Companies
in the Biotechnology industry.

( Industry Median: -295.57 vs. NAS:TECH: 26.07 )

Bio-Techne's 5-Year Average Operating Margin % Growth Rate was -4.40% per year.

Bio-Techne's Operating Income for the three months ended in Jun. 2021 was $74.0 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2021 was $242.7 Mil.


Bio-Techne Operating Margin % Historical Data

The historical data trend for Bio-Techne's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Operating Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.68 24.76 20.60 20.15 26.07

Bio-Techne Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.48 24.04 22.74 28.18 28.56

Competitive Comparison

For the Biotechnology subindustry, Bio-Techne's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Bio-Techne Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Bio-Techne's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Operating Margin % falls into.



Bio-Techne Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Bio-Techne's Operating Margin % for the fiscal year that ended in Jun. 2021 is calculated as

Operating Margin %=Operating Income (A: Jun. 2021 ) / Revenue (A: Jun. 2021 )
=242.69 / 931.032
=26.07 %

Bio-Techne's Operating Margin % for the quarter that ended in Jun. 2021 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2021 ) / Revenue (Q: Jun. 2021 )
=73.976 / 259.028
=28.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Techne  (NAS:TECH) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Bio-Techne Operating Margin % Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne Business Description

Bio-Techne logo
Industry
Healthcare » Biotechnology NAICS : 325414 SIC : 2836
Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Executives
Hippel James officer: Chief Financial Officer 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413
Kummeth Charles R. director, officer: Chief Executive Officer 425 MARTINGALE ROAD SUITE 1000 SCHAUMBURG IL 60173-2213
Furlow Brenda S. officer: SVP - General Counsel 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413
Eansor Norman David officer: President-Protein Sciences 8100 SOUTHPARK WAY, A-8 LITTLETON CO 80120
Kelderman Kim officer: Pres. Diagnostics & Genom 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413
Bushman Julie L director 185 SOUTH 84TH STREET, SUITE 200 MILWAUKEE WI 53214
Wiens Harold J director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: WIENS HAROLD J a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Baumgartner Robert V director 5775 WAYZATA BOULEVARD, SUITE 400 MINNEAPOLIS MN 55416
Higgins John L director 11119 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA CA 92037
Nusse Roeland director 473 TENNESSEE PALO ALTO CA 94306
Keegan Joseph D director C/O MOLECULAR DEVICES CORP 1311 ORLEANS DRIVE SUNNYVALE CA 94089
Seth Alpna director 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413
Steer Randolph C director 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413
Vessey Rupert director C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Dinarello Charles A director 333 15TH STREET BOULDER CO 80302

Bio-Techne Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)